Xarelto Liability Suit: Is Label 'Silent' About Increased Bleeding Risk?
Executive Summary
Even after multiple bellweather wins, Janssen and Bayer still face claims they did not warn doctors about concomitant use with Plavix and aspirin; as case begins in Philadelphia, plaintiff's attorney tells jury the firms were 'silent,' while defense points to doctors' testimony that a different warning would not have changed their prescribing.
You may also be interested in...
A Return Trip For Kessler At US FDA? It Wouldn’t Be The First Time It’s Happened
Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.
After 5-Year Winning Streak, Xarelto Makers Settle Personal Injury Suits
Bayer and Johnson & Johnson agree to resolve approximately 25,000 claims in federal and state courts for $775m, almost 13% of Xarelto's 2018 sales.
Strong Xarelto Label Warnings Lead To Another Jury Win For Bayer And Janssen
Philadelphia jurors find that warnings of bleeding risk with Xarelto are adequate, giving companies 5-0 litigation score; sixth trial in June.